ID   KIME_HUMAN              Reviewed;         396 AA.
AC   Q03426;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   15-MAR-2017, entry version 187.
DE   RecName: Full=Mevalonate kinase;
DE            Short=MK;
DE            EC=2.7.1.36;
GN   Name=MVK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT MEVA THR-301.
RX   PubMed=1377680;
RA   Schafer B.L., Bishop R.W., Kratunis V.J., Kalinowski S.S.,
RA   Mosley S.T., Gibson K.M., Tanaka R.D.;
RT   "Molecular cloning of human mevalonate kinase and identification of a
RT   missense mutation in the genetic disease mevalonic aciduria.";
RL   J. Biol. Chem. 267:13229-13238(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hepatoma;
RX   PubMed=8302606;
RA   Graef E., Caselmann W.H., Wells J., Koshy R.;
RT   "Insertional activation of mevalonate kinase by hepatitis B virus DNA
RT   in a human hepatoma cell line.";
RL   Oncogene 9:81-87(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS HIDS PRO-20; PRO-39;
RP   LEU-135; THR-148; THR-268 AND ILE-377, AND VARIANTS MEVA PRO-20;
RP   PHE-264; THR-268; MET-310 AND THR-334.
RX   PubMed=11313768; DOI=10.1038/sj.ejhg.5200595;
RA   Houten S.M., Koster J., Romeijn G.-J., Frenkel J., Di Rocco M.,
RA   Caruso U., Landrieu P., Kelley R.I., Kuis W., Poll-The B.T.,
RA   Gibson K.M., Wanders R.J.A., Waterham H.R.;
RT   "Organization of the mevalonate kinase (MVK) gene and identification
RT   of novel mutations causing mevalonic aciduria and
RT   hyperimmunoglobulinaemia D and periodic fever syndrome.";
RL   Eur. J. Hum. Genet. 9:253-259(2001).
RN   [4]
RP   ERRATUM.
RA   Houten S.M., Koster J., Romeijn G.-J., Frenkel J., Di Rocco M.,
RA   Caruso U., Landrieu P., Kelley R.I., Kuis W., Poll-The B.T.,
RA   Gibson K.M., Wanders R.J.A., Waterham H.R.;
RL   Eur. J. Hum. Genet. 9:651-651(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14730012; DOI=10.1242/jcs.00910;
RA   Hogenboom S., Tuyp J.J., Espeel M., Koster J., Wanders R.J.,
RA   Waterham H.R.;
RT   "Mevalonate kinase is a cytosolic enzyme in humans.";
RL   J. Cell Sci. 117:631-639(2004).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   INVOLVEMENT IN POROK3, AND VARIANTS POROK3 ARG-12; PRO-41; ARG-202;
RP   PRO-255; PRO-279; ASP-291; ARG-312; SER-365 AND SER-376.
RX   PubMed=22983302; DOI=10.1038/ng.2409;
RA   Zhang S.Q., Jiang T., Li M., Zhang X., Ren Y.Q., Wei S.C., Sun L.D.,
RA   Cheng H., Li Y., Yin X.Y., Hu Z.M., Wang Z.Y., Liu Y., Guo B.R.,
RA   Tang H.Y., Tang X.F., Ding Y.T., Wang J.B., Li P., Wu B.Y., Wang W.,
RA   Yuan X.F., Hou J.S., Ha W.W., Wang W.J., Zhai Y.J., Wang J.,
RA   Qian F.F., Zhou F.S., Chen G., Zuo X.B., Zheng X.D., Sheng Y.J.,
RA   Gao J.P., Liang B., Li P., Zhu J., Xiao F.L., Wang P.G., Cui Y.,
RA   Li H., Liu S.X., Gao M., Fan X., Shen S.K., Zeng M., Sun G.Q., Xu Y.,
RA   Hu J.C., He T.T., Li Y.R., Yang H.M., Wang J., Yu Z.Y., Zhang H.F.,
RA   Hu X., Yang K., Wang J., Zhao S.X., Zhou Y.W., Liu J.J., Du W.D.,
RA   Zhang L., Xia K., Yang S., Wang J., Zhang X.J.;
RT   "Exome sequencing identifies MVK mutations in disseminated superficial
RT   actinic porokeratosis.";
RL   Nat. Genet. 44:1156-1160(2012).
RN   [9]
RP   INVOLVEMENT IN POROK3.
RX   PubMed=24781643; DOI=10.1007/s00403-014-1465-7;
RA   Zeng K., Zhang Q.G., Li L., Duan Y., Liang Y.H.;
RT   "Splicing mutation in MVK is a cause of porokeratosis of Mibelli.";
RL   Arch. Dermatol. Res. 306:749-755(2014).
RN   [10]
RP   VARIANTS MEVA ILE-243; PHE-264; PRO-265 AND THR-268.
RX   PubMed=10417275; DOI=10.1086/302489;
RA   Hinson D.D., Ross R.M., Krisans S., Shaw J.L., Kozich V.,
RA   Rolland M.-O., Divry P., Mancini J., Hoffmann G.F., Gibson K.M.;
RT   "Identification of a mutation cluster in mevalonate kinase deficiency,
RT   including a new mutation in a patient of Mennonite ancestry.";
RL   Am. J. Hum. Genet. 65:327-335(1999).
RN   [11]
RP   VARIANTS MEVA MET-310 AND THR-334.
RX   PubMed=10401001; DOI=10.1093/hmg/8.8.1523;
RA   Houten S.M., Romeijn G.J., Koster J., Gray R.G.F., Darbyshire P.,
RA   Smit G.P.A., de Klerk J.B.C., Duran R., Gibson K.M., Wanders R.J.A.,
RA   Waterham H.R.;
RT   "Identification and characterization of three novel missense mutations
RT   in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of
RT   isoprene biosynthesis.";
RL   Hum. Mol. Genet. 8:1523-1528(1999).
RN   [12]
RP   VARIANTS HIDS PRO-20; THR-268 AND ILE-377.
RX   PubMed=10369261; DOI=10.1038/9691;
RA   Houten S.M., Kuis W., Duran M., de Koning T.J., van Royen-Kerkhof A.,
RA   Romeijn G.J., Frenkel J., Dorland L., de Barse M.M.J.,
RA   Huijbers W.A.R., Rijkers G.T., Waterham H.R., Wanders R.J.A.,
RA   Poll-The B.T.;
RT   "Mutations in MVK, encoding mevalonate kinase, cause
RT   hyperimmunoglobulinaemia D and periodic fever syndrome.";
RL   Nat. Genet. 22:175-177(1999).
RN   [13]
RP   VARIANTS HIDS LEU-167; THR-268 AND ILE-377.
RX   PubMed=10369262; DOI=10.1038/9696;
RA   Drenth J.P.H., Cuisset L., Grateau G., Vasseur C.,
RA   van der Velde-Visser S.D., de Jong J.G.N., Beckmann J.S.,
RA   van der Meer J.W.M., Delpech M.;
RT   "Mutations in the gene encoding mevalonate kinase cause hyper-IgD and
RT   periodic fever syndrome.";
RL   Nat. Genet. 22:178-181(1999).
RN   [14]
RP   VARIANTS HIDS ASN-20; PRO-20; PRO-39; LEU-150; LEU-167; ARG-202;
RP   GLN-215; THR-268; SER-309; ARG-326 AND ILE-377, VARIANT MEVA THR-334,
RP   AND VARIANT ASN-52.
RX   PubMed=11313769; DOI=10.1038/sj.ejhg.5200614;
RA   Cuisset L., Drenth J.P.H., Simon A., Vincent M.-F.,
RA   van der Velde-Visser S.D., van der Meer J.W.M., Grateau G.,
RA   Delpech M.;
RT   "Molecular analysis of MVK mutations and enzymatic activity in hyper-
RT   IgD and periodic fever syndrome.";
RL   Eur. J. Hum. Genet. 9:260-266(2001).
RN   [15]
RP   VARIANTS HIDS GLN-20; ILE-132; THR-148; ARG-171; GLU-211; GLN-215;
RP   ILE-250; ARG-265; THR-268; MET-310; VAL-376 AND ILE-377, AND VARIANTS
RP   ASN-52 AND MET-356.
RX   PubMed=15536479; DOI=10.1038/sj.ejhg.5201323;
RA   D'Osualdo A., Picco P., Caroli F., Gattorno M., Giacchino R.,
RA   Fortini P., Corona F., Tommasini A., Salvi G., Specchia F., Obici L.,
RA   Meini A., Ricci A., Seri M., Ravazzolo R., Martini A., Ceccherini I.;
RT   "MVK mutations and associated clinical features in Italian patients
RT   affected with autoinflammatory disorders and recurrent fever.";
RL   Eur. J. Hum. Genet. 13:314-320(2005).
CC   -!- FUNCTION: May be a regulatory site in cholesterol biosynthetic
CC       pathway.
CC   -!- CATALYTIC ACTIVITY: ATP + (R)-mevalonate = ADP + (R)-5-
CC       phosphomevalonate.
CC   -!- ENZYME REGULATION: Farnesyl- and geranyl-pyrophosphates are
CC       competitive inhibitors.
CC   -!- PATHWAY: Isoprenoid biosynthesis; isopentenyl diphosphate
CC       biosynthesis via mevalonate pathway; isopentenyl diphosphate from
CC       (R)-mevalonate: step 1/3.
CC   -!- SUBUNIT: Homodimer.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-740630, EBI-740630;
CC       Q9NUX5:POT1; NbExp=2; IntAct=EBI-740630, EBI-752420;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14730012}.
CC   -!- DISEASE: Mevalonic aciduria (MEVA) [MIM:610377]: Accumulation of
CC       mevalonic acid which causes a variety of symptoms such as
CC       psychomotor retardation, dysmorphic features, cataracts,
CC       hepatosplenomegaly, lymphadenopathy, anemia, hypotonia, myopathy,
CC       and ataxia. {ECO:0000269|PubMed:10401001,
CC       ECO:0000269|PubMed:10417275, ECO:0000269|PubMed:11313768,
CC       ECO:0000269|PubMed:11313769, ECO:0000269|PubMed:1377680}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Hyperimmunoglobulinemia D and periodic fever syndrome
CC       (HIDS) [MIM:260920]: Autosomal recessive disease characterized by
CC       recurrent episodes of unexplained high fever associated with skin
CC       rash, diarrhea, adenopathy (swollen, tender lymph nodes),
CC       arthralgias and/or arthritis. Concentration of IgD, and often IgA,
CC       are above normal. {ECO:0000269|PubMed:10369261,
CC       ECO:0000269|PubMed:10369262, ECO:0000269|PubMed:11313768,
CC       ECO:0000269|PubMed:11313769, ECO:0000269|PubMed:15536479}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Porokeratosis 3, multiple types (POROK3) [MIM:175900]: A
CC       form of porokeratosis, a disorder of faulty keratinization
CC       characterized by one or more atrophic patches surrounded by a
CC       distinctive hyperkeratotic ridgelike border called the cornoid
CC       lamella. The keratotic lesions can progress to overt cutaneous
CC       neoplasms, typically squamous cell carcinomas. Multiple clinical
CC       variants of porokeratosis are recognized, including porokeratosis
CC       of Mibelli, linear porokeratosis, disseminated superficial actinic
CC       porokeratosis, palmoplantar porokeratosis, and punctate
CC       porokeratosis. Different clinical presentations can be observed
CC       among members of the same family. Individuals expressing more than
CC       one variant have also been reported. {ECO:0000269|PubMed:22983302,
CC       ECO:0000269|PubMed:24781643}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the GHMP kinase family. Mevalonate kinase
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA53059.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditary
CC       autoinflammatory disorders mutations;
CC       URL="http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=3";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M88468; AAB59362.1; -; mRNA.
DR   EMBL; X75311; CAA53060.1; -; mRNA.
DR   EMBL; X75311; CAA53059.1; ALT_INIT; mRNA.
DR   EMBL; AF217535; AAF82407.1; -; Genomic_DNA.
DR   EMBL; AF217528; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; AF217529; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; AF217530; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; AF217531; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; AF217532; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; AF217533; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; AF217534; AAF82407.1; JOINED; Genomic_DNA.
DR   EMBL; BC016140; AAH16140.1; -; mRNA.
DR   CCDS; CCDS9132.1; -.
DR   PIR; A42919; A42919.
DR   RefSeq; NP_000422.1; NM_000431.3.
DR   RefSeq; NP_001107657.1; NM_001114185.2.
DR   RefSeq; NP_001288111.1; NM_001301182.1.
DR   RefSeq; XP_016874803.1; XM_017019314.1.
DR   UniGene; Hs.130607; -.
DR   PDB; 2R3V; X-ray; 2.50 A; A/B/C/D=1-396.
DR   PDBsum; 2R3V; -.
DR   ProteinModelPortal; Q03426; -.
DR   SMR; Q03426; -.
DR   BioGrid; 110683; 16.
DR   IntAct; Q03426; 3.
DR   MINT; MINT-1473671; -.
DR   STRING; 9606.ENSP00000228510; -.
DR   DrugBank; DB04695; FARNESYL THIOPYROPHOSPHATE.
DR   GuidetoPHARMACOLOGY; 640; -.
DR   SwissLipids; SLP:000001240; -.
DR   iPTMnet; Q03426; -.
DR   PhosphoSitePlus; Q03426; -.
DR   BioMuta; MVK; -.
DR   DMDM; 417215; -.
DR   EPD; Q03426; -.
DR   MaxQB; Q03426; -.
DR   PaxDb; Q03426; -.
DR   PeptideAtlas; Q03426; -.
DR   PRIDE; Q03426; -.
DR   DNASU; 4598; -.
DR   Ensembl; ENST00000228510; ENSP00000228510; ENSG00000110921.
DR   Ensembl; ENST00000539575; ENSP00000443551; ENSG00000110921.
DR   GeneID; 4598; -.
DR   KEGG; hsa:4598; -.
DR   UCSC; uc009zvk.4; human.
DR   CTD; 4598; -.
DR   DisGeNET; 4598; -.
DR   GeneCards; MVK; -.
DR   HGNC; HGNC:7530; MVK.
DR   HPA; HPA016961; -.
DR   MalaCards; MVK; -.
DR   MIM; 175900; phenotype.
DR   MIM; 251170; gene.
DR   MIM; 260920; phenotype.
DR   MIM; 610377; phenotype.
DR   neXtProt; NX_Q03426; -.
DR   OpenTargets; ENSG00000110921; -.
DR   Orphanet; 79152; Disseminated superficial actinic porokeratosis.
DR   Orphanet; 343; Hyperimmunoglobulinemia D with periodic fever.
DR   Orphanet; 29; Mevalonic aciduria.
DR   PharmGKB; PA31331; -.
DR   eggNOG; KOG1511; Eukaryota.
DR   eggNOG; COG1577; LUCA.
DR   GeneTree; ENSGT00390000011860; -.
DR   HOVERGEN; HBG000402; -.
DR   InParanoid; Q03426; -.
DR   KO; K00869; -.
DR   OMA; NRWTKED; -.
DR   OrthoDB; EOG091G05QV; -.
DR   PhylomeDB; Q03426; -.
DR   TreeFam; TF313775; -.
DR   BioCyc; MetaCyc:ENSG00000110921-MONOMER; -.
DR   BRENDA; 2.7.1.36; 2681.
DR   Reactome; R-HSA-191273; Cholesterol biosynthesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   SABIO-RK; Q03426; -.
DR   UniPathway; UPA00057; UER00098.
DR   ChiTaRS; MVK; human.
DR   EvolutionaryTrace; Q03426; -.
DR   GeneWiki; Mevalonate_kinase; -.
DR   GenomeRNAi; 4598; -.
DR   PRO; PR:Q03426; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000110921; -.
DR   CleanEx; HS_MVK; -.
DR   ExpressionAtlas; Q03426; baseline and differential.
DR   Genevisible; Q03426; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004496; F:mevalonate kinase activity; IDA:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019287; P:isopentenyl diphosphate biosynthetic process, mevalonate pathway; IBA:GO_Central.
DR   GO; GO:0008299; P:isoprenoid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:BHF-UCL.
DR   Gene3D; 3.30.230.10; -; 1.
DR   Gene3D; 3.30.70.890; -; 1.
DR   InterPro; IPR013750; GHMP_kinase_C_dom.
DR   InterPro; IPR006204; GHMP_kinase_N_dom.
DR   InterPro; IPR006203; GHMP_knse_ATP-bd_CS.
DR   InterPro; IPR006205; Mev_gal_kin.
DR   InterPro; IPR006206; Mevalonate/galactokinase.
DR   InterPro; IPR020568; Ribosomal_S5_D2-typ_fold.
DR   InterPro; IPR014721; Ribosomal_S5_D2-typ_fold_subgr.
DR   Pfam; PF08544; GHMP_kinases_C; 1.
DR   Pfam; PF00288; GHMP_kinases_N; 1.
DR   PRINTS; PR00959; MEVGALKINASE.
DR   SUPFAM; SSF54211; SSF54211; 1.
DR   SUPFAM; SSF55060; SSF55060; 1.
DR   TIGRFAMs; TIGR00549; mevalon_kin; 1.
DR   PROSITE; PS00627; GHMP_KINASES_ATP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cataract; Cholesterol biosynthesis;
KW   Cholesterol metabolism; Complete proteome; Cytoplasm;
KW   Disease mutation; Kinase; Lipid biosynthesis; Lipid metabolism;
KW   Nucleotide-binding; Polymorphism; Reference proteome;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism; Transferase.
FT   CHAIN         1    396       Mevalonate kinase.
FT                                /FTId=PRO_0000156657.
FT   NP_BIND     138    148       ATP. {ECO:0000250}.
FT   ACT_SITE    204    204       Proton acceptor. {ECO:0000250}.
FT   BINDING      55     55       ATP. {ECO:0000250}.
FT   BINDING     135    135       ATP. {ECO:0000250}.
FT   VARIANT      12     12       G -> R (in POROK3).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075036.
FT   VARIANT      20     20       H -> N (in HIDS; dbSNP:rs11544299).
FT                                {ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_010956.
FT   VARIANT      20     20       H -> P (in HIDS and MEVA;
FT                                dbSNP:rs104895295).
FT                                {ECO:0000269|PubMed:10369261,
FT                                ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_004022.
FT   VARIANT      20     20       H -> Q (in HIDS; dbSNP:rs104895335).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029519.
FT   VARIANT      39     39       L -> P (in HIDS; dbSNP:rs104895296).
FT                                {ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_010957.
FT   VARIANT      41     41       L -> P (in POROK3; dbSNP:rs397514571).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075037.
FT   VARIANT      52     52       S -> N (in dbSNP:rs7957619).
FT                                {ECO:0000269|PubMed:11313769,
FT                                ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_010958.
FT   VARIANT     132    132       V -> I (in HIDS; dbSNP:rs104895336).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029520.
FT   VARIANT     135    135       S -> L (in HIDS; dbSNP:rs104895297).
FT                                {ECO:0000269|PubMed:11313768}.
FT                                /FTId=VAR_010959.
FT   VARIANT     148    148       A -> T (in HIDS; dbSNP:rs104895298).
FT                                {ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_010960.
FT   VARIANT     150    150       S -> L (in HIDS; dbSNP:rs747116992).
FT                                {ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_010961.
FT   VARIANT     167    167       P -> L (in HIDS; dbSNP:rs104895300).
FT                                {ECO:0000269|PubMed:10369262,
FT                                ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_004023.
FT   VARIANT     171    171       G -> R (in HIDS; dbSNP:rs104895337).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029521.
FT   VARIANT     202    202       G -> R (in HIDS and POROK3;
FT                                dbSNP:rs104895301).
FT                                {ECO:0000269|PubMed:11313769,
FT                                ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_010962.
FT   VARIANT     211    211       G -> E (in HIDS; dbSNP:rs104895325).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029522.
FT   VARIANT     215    215       R -> Q (in HIDS; dbSNP:rs104895303).
FT                                {ECO:0000269|PubMed:11313769,
FT                                ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_010963.
FT   VARIANT     243    243       T -> I (in MEVA; dbSNP:rs104895314).
FT                                {ECO:0000269|PubMed:10417275}.
FT                                /FTId=VAR_010964.
FT   VARIANT     250    250       V -> I (in HIDS; dbSNP:rs104895339).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029523.
FT   VARIANT     255    255       L -> P (in POROK3; dbSNP:rs397514570).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075038.
FT   VARIANT     264    264       L -> F (in MEVA; dbSNP:rs104895315).
FT                                {ECO:0000269|PubMed:10417275,
FT                                ECO:0000269|PubMed:11313768}.
FT                                /FTId=VAR_010965.
FT   VARIANT     265    265       L -> P (in MEVA; dbSNP:rs104895316).
FT                                {ECO:0000269|PubMed:10417275}.
FT                                /FTId=VAR_010966.
FT   VARIANT     265    265       L -> R (in HIDS; dbSNP:rs104895316).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029524.
FT   VARIANT     268    268       I -> T (in HIDS and MEVA;
FT                                dbSNP:rs104895304).
FT                                {ECO:0000269|PubMed:10369261,
FT                                ECO:0000269|PubMed:10369262,
FT                                ECO:0000269|PubMed:10417275,
FT                                ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:11313769,
FT                                ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_004024.
FT   VARIANT     279    279       L -> P (in POROK3).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075039.
FT   VARIANT     291    291       Y -> D (in POROK3).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075040.
FT   VARIANT     301    301       N -> T (in MEVA; diminished activity;
FT                                dbSNP:rs28934896).
FT                                {ECO:0000269|PubMed:1377680}.
FT                                /FTId=VAR_004025.
FT   VARIANT     309    309       G -> S (in HIDS; dbSNP:rs104895305).
FT                                {ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_010967.
FT   VARIANT     310    310       V -> M (in MEVA and HIDS;
FT                                dbSNP:rs104895319).
FT                                {ECO:0000269|PubMed:10401001,
FT                                ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_009068.
FT   VARIANT     312    312       H -> R (in POROK3).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075041.
FT   VARIANT     326    326       G -> R (in HIDS; dbSNP:rs104895308).
FT                                {ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_010968.
FT   VARIANT     334    334       A -> T (in MEVA; dbSNP:rs104895317).
FT                                {ECO:0000269|PubMed:10401001,
FT                                ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:11313769}.
FT                                /FTId=VAR_004026.
FT   VARIANT     335    335       G -> S (in dbSNP:rs11614976).
FT                                /FTId=VAR_029525.
FT   VARIANT     356    356       T -> M (in dbSNP:rs104895342).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029526.
FT   VARIANT     365    365       F -> S (in POROK3; dbSNP:rs398122911).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075042.
FT   VARIANT     376    376       G -> S (in POROK3).
FT                                {ECO:0000269|PubMed:22983302}.
FT                                /FTId=VAR_075043.
FT   VARIANT     376    376       G -> V (in HIDS; dbSNP:rs104895340).
FT                                {ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_029527.
FT   VARIANT     377    377       V -> I (in HIDS; most frequent mutation;
FT                                dbSNP:rs28934897).
FT                                {ECO:0000269|PubMed:10369261,
FT                                ECO:0000269|PubMed:10369262,
FT                                ECO:0000269|PubMed:11313768,
FT                                ECO:0000269|PubMed:11313769,
FT                                ECO:0000269|PubMed:15536479}.
FT                                /FTId=VAR_004027.
FT   STRAND        4     17       {ECO:0000244|PDB:2R3V}.
FT   TURN         19     21       {ECO:0000244|PDB:2R3V}.
FT   HELIX        22     24       {ECO:0000244|PDB:2R3V}.
FT   STRAND       28     43       {ECO:0000244|PDB:2R3V}.
FT   STRAND       45     52       {ECO:0000244|PDB:2R3V}.
FT   TURN         54     56       {ECO:0000244|PDB:2R3V}.
FT   STRAND       59     63       {ECO:0000244|PDB:2R3V}.
FT   HELIX        64     69       {ECO:0000244|PDB:2R3V}.
FT   HELIX        85     95       {ECO:0000244|PDB:2R3V}.
FT   HELIX       103    119       {ECO:0000244|PDB:2R3V}.
FT   STRAND      122    125       {ECO:0000244|PDB:2R3V}.
FT   STRAND      129    137       {ECO:0000244|PDB:2R3V}.
FT   STRAND      141    143       {ECO:0000244|PDB:2R3V}.
FT   HELIX       145    160       {ECO:0000244|PDB:2R3V}.
FT   TURN        167    171       {ECO:0000244|PDB:2R3V}.
FT   STRAND      173    175       {ECO:0000244|PDB:2R3V}.
FT   HELIX       179    196       {ECO:0000244|PDB:2R3V}.
FT   STRAND      197    199       {ECO:0000244|PDB:2R3V}.
FT   HELIX       203    210       {ECO:0000244|PDB:2R3V}.
FT   STRAND      212    216       {ECO:0000244|PDB:2R3V}.
FT   STRAND      221    223       {ECO:0000244|PDB:2R3V}.
FT   STRAND      230    236       {ECO:0000244|PDB:2R3V}.
FT   HELIX       243    256       {ECO:0000244|PDB:2R3V}.
FT   HELIX       258    283       {ECO:0000244|PDB:2R3V}.
FT   HELIX       288    307       {ECO:0000244|PDB:2R3V}.
FT   HELIX       313    323       {ECO:0000244|PDB:2R3V}.
FT   TURN        324    326       {ECO:0000244|PDB:2R3V}.
FT   STRAND      328    331       {ECO:0000244|PDB:2R3V}.
FT   STRAND      336    343       {ECO:0000244|PDB:2R3V}.
FT   HELIX       350    361       {ECO:0000244|PDB:2R3V}.
FT   TURN        362    364       {ECO:0000244|PDB:2R3V}.
FT   STRAND      366    373       {ECO:0000244|PDB:2R3V}.
FT   STRAND      377    380       {ECO:0000244|PDB:2R3V}.
FT   HELIX       387    392       {ECO:0000244|PDB:2R3V}.
SQ   SEQUENCE   396 AA;  42451 MW;  C8F6B629B58CD229 CRC64;
     MLSEVLLVSA PGKVILHGEH AVVHGKVALA VSLNLRTFLR LQPHSNGKVD LSLPNIGIKR
     AWDVARLQSL DTSFLEQGDV TTPTSEQVEK LKEVAGLPDD CAVTERLAVL AFLYLYLSIC
     RKQRALPSLD IVVWSELPPG AGLGSSAAYS VCLAAALLTV CEEIPNPLKD GDCVNRWTKE
     DLELINKWAF QGERMIHGNP SGVDNAVSTW GGALRYHQGK ISSLKRSPAL QILLTNTKVP
     RNTRALVAGV RNRLLKFPEI VAPLLTSIDA ISLECERVLG EMGEAPAPEQ YLVLEELIDM
     NQHHLNALGV GHASLDQLCQ VTRARGLHSK LTGAGGGGCG ITLLKPGLEQ PEVEATKQAL
     TSCGFDCLET SIGAPGVSIH SATSLDSRVQ QALDGL
//
